Top

Published in:

01-06-2015 | Review

Circulating tumor cell clusters-associated gene plakoglobin and breast cancer survival

Authors: Lingeng Lu, Hongmei Zeng, Xinsheng Gu, Wenxue Ma

Published in: Breast Cancer Research and Treatment | Issue 3/2015

Abstract

Breast cancer recurrence is a major cause of the disease-specific death. Circulating tumor cells (CTCs) are negatively associated with breast cancer survival. Plakoglobin, a cell adhesion protein, was recently reported as a determinant of CTCs types, single or clustered ones. Here, we aim to summarize the studies on the roles of plakoglobin and evaluate the association of plakoglobin and breast cancer survival. Plakoglobin as a key component in both cell adhesion and the signaling pathways was briefly reviewed first. Then the double-edge functions of plakoglobin in tumors and its association with CTCs and breast cancer metastasis were introduced. Finally, based on an open-access database, the association between plakoglobin and breast cancer survival was investigated using univariate and multivariate survival analyses. Plakoglobin may be a molecule functioning as a double-edge sword. Loss of plakoglobin expression leads to increased motility of epithelial cells, thereby promoting epithelial–mesenchymal transition and further metastasis of cancer. However, studies also show that plakoglobin can function as an oncogene. High expression of plakoglobin results in clustered tumor cells in circulation with high metastatic potential in breast cancer and shortened patient survival. Plakoglobin may be a potential prognostic biomarker that can be exploited to develop as a therapeutic target for breast cancer.

Siegel RL, Miller KD, Jemal A (2015) Cancer statistics. CA Cancer J Clin 65(1):5–29. doi:10.3322/caac.21254 CrossRefPubMed

Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M, Marubini E (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347(16):1227–1232. doi:10.1056/NEJMoa020989 CrossRefPubMed

Blichert-Toft M, Nielsen M, During M, Moller S, Rank F, Overgaard M, Mouridsen HT (2008) Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. Acta Oncol 47(4):672–681. doi:10.1080/02841860801971439 CrossRefPubMed

Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J (2006) Loco-regional recurrence after mastectomy in high-risk breast cancer–risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials. Radiother Oncol 79(2):147–155. doi:10.1016/j.radonc.2006.04.006 CrossRefPubMed

Visvader JE, Lindeman GJ (2012) Cancer stem cells: current status and evolving complexities. Cell Stem Cell 10(6):717–728. doi:10.1016/j.stem.2012.05.007 CrossRefPubMed

El Helou R, Wicinski J, Guille A, Adelaide J, Finetti P, Bertucci F, Chaffanet M, Birnbaum D, Charafe-Jauffret E, Ginestier C (2014) Brief reports: a distinct DNA methylation signature defines breast cancer stem cells and predicts cancer outcome. Stem Cells 32(11):3031–3036. doi:10.1002/stem.1792 CrossRefPubMed

Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353(8):793–802. doi:10.1056/NEJMoa050434 CrossRefPubMed

Berman AT, Thukral AD, Hwang WT, Solin LJ, Vapiwala N (2013) Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment. Clin Breast Cancer 13(2):88–94. doi:10.1016/j.clbc.2012.11.001 CrossRefPubMed

Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, Datar RH, Cote RJ (2006) Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 12(19):5615–5621. doi:10.1158/1078-0432.CCR-06-0169 CrossRefPubMed

10.

Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449(7162):557–563. doi:10.1038/nature06188 CrossRefPubMed

11.

Kasai T, Chen L, Mizutani A, Kudoh T, Murakami H, Fu L, Seno M (2014) Cancer stem cells converted from pluripotent stem cells and the cancerous niche. J Stem Cells Regen Med 10(1):2–7PubMedCentralPubMed

12.

Aggarwal C, Meropol NJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, Cohen SJ (2013) Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann Oncol 24(2):420–428. doi:10.1093/annonc/mds336 CrossRefPubMed

13.

Deneve E, Riethdorf S, Ramos J, Nocca D, Coffy A, Daures JP, Maudelonde T, Fabre JM, Pantel K, Alix-Panabieres C (2013) Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem 59(9):1384–1392. doi:10.1373/clinchem.2013.202846 CrossRefPubMed

14.

Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, Ward T, Blackhall FH, Dive C (2012) Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 30(5):525–532. doi:10.1200/JCO.2010.33.3716 CrossRefPubMed

15.

Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, Ward TH, Ferraldeschi R, Hughes A, Clack G, Ranson M, Dive C, Blackhall FH (2011) Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 29(12):1556–1563. doi:10.1200/JCO.2010.28.7045 CrossRefPubMed

16.

Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, Heller G (2009) Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 10(3):233–239. doi:10.1016/S1470-2045(08)70340-1 CrossRefPubMedCentralPubMed

17.

Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G, Liu J, Pantel K (2012) Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 18(20):5701–5710. doi:10.1158/1078-0432.CCR-12-1587 CrossRefPubMed

18.

Alix-Panabieres C, Pantel K (2014) Challenges in circulating tumour cell research. Nat Rev Cancer 14(9):623–631. doi:10.1038/nrc3820 CrossRefPubMed

19.

Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bauerle T, Wallwiener M, Holland-Letz T, Hofner T, Sprick M, Scharpff M, Marme F, Sinn HP, Pantel K, Weichert W, Trumpp A (2013) Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31(6):539–544. doi:10.1038/nbt.2576 CrossRefPubMed

20.

Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H, Brannigan BW, Kapur R, Stott SL, Shioda T, Ramaswamy S, Ting DT, Lin CP, Toner M, Haber DA, Maheswaran S (2014) Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158(5):1110–1122. doi:10.1016/j.cell.2014.07.013 CrossRefPubMed

21.

Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C (2014) Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol 11(3):129–144. doi:10.1038/nrclinonc.2013.253 CrossRefPubMed

22.

Labelle M, Begum S, Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial–mesenchymal-like transition and promotes metastasis. Cancer Cell 20(5):576–590. doi:10.1016/j.ccr.2011.09.009 CrossRefPubMedCentralPubMed

23.

Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S (2013) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339(6119):580–584. doi:10.1126/science.1228522 CrossRefPubMedCentralPubMed

24.

Wels J, Kaplan RN, Rafii S, Lyden D (2008) Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev 22(5):559–574. doi:10.1101/gad.1636908 CrossRefPubMedCentralPubMed

25.

Psaila B, Lyden D (2009) The metastatic niche: adapting the foreign soil. Nat Rev Cancer 9(4):285–293. doi:10.1038/nrc2621 CrossRefPubMedCentralPubMed

26.

Aktary Z, Pasdar M (2012) Plakoglobin: role in tumorigenesis and metastasis. Int J Cell Biol 2012:189521. doi:10.1155/2012/189521 CrossRefPubMedCentralPubMed

27.

Todorovic V, Desai BV, Patterson MJ, Amargo EV, Dubash AD, Yin T, Jones JC, Green KJ (2010) Plakoglobin regulates cell motility through Rho- and fibronectin-dependent Src signaling. J Cell Sci 123(Pt 20):3576–3586. doi:10.1242/jcs.070391 CrossRefPubMedCentralPubMed

28.

Shair KH, Schnegg CI, Raab-Traub N (2008) EBV latent membrane protein 1 effects on plakoglobin, cell growth, and migration. Cancer Res 68(17):6997–7005. doi:10.1158/0008-5472.CAN-08-1178 CrossRefPubMedCentralPubMed

29.

Rieger-Christ KM, Ng L, Hanley RS, Durrani O, Ma H, Yee AS, Libertino JA, Summerhayes IC (2005) Restoration of plakoglobin expression in bladder carcinoma cell lines suppresses cell migration and tumorigenic potential. Br J Cancer 92(12):2153–2159. doi:10.1038/sj.bjc.6602651 CrossRefPubMedCentralPubMed

30.

Yin T, Getsios S, Caldelari R, Kowalczyk AP, Muller EJ, Jones JC, Green KJ (2005) Plakoglobin suppresses keratinocyte motility through both cell-cell adhesion-dependent and -independent mechanisms. Proc Natl Acad Sci USA 102(15):5420–5425. doi:10.1073/pnas.0501676102 CrossRefPubMedCentralPubMed

31.

Kolligs FT, Kolligs B, Hajra KM, Hu G, Tani M, Cho KR, Fearon ER (2000) Gamma-catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of beta-catenin. Genes Dev 14(11):1319–1331PubMedCentralPubMed

32.

Hakimelahi S, Parker HR, Gilchrist AJ, Barry M, Li Z, Bleackley RC, Pasdar M (2000) Plakoglobin regulates the expression of the anti-apoptotic protein BCL-2. J Biol Chem 275(15):10905–10911CrossRefPubMed

33.

Shiina H, Breault JE, Basset WW, Enokida H, Urakami S, Li LC, Okino ST, Deguchi M, Kaneuchi M, Terashima M, Yoneda T, Shigeno K, Carroll PR, Igawa M, Dahiya R (2005) Functional loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer. Cancer Res 65(6):2130–2138. doi:10.1158/0008-5472.CAN-04-3398 CrossRefPubMed

34.

Cowin P, Kapprell HP, Franke WW, Tamkun J, Hynes RO (1986) Plakoglobin: a protein common to different kinds of intercellular adhering junctions. Cell 46(7):1063–1073CrossRefPubMed

35.

Knudsen KA, Wheelock MJ (1992) Plakoglobin, or an 83-kD homologue distinct from beta-catenin, interacts with E-cadherin and N-cadherin. J Cell Biol 118(3):671–679CrossRefPubMed

36.

Hu P, Berkowitz P, Madden VJ, Rubenstein DS (2006) Stabilization of plakoglobin and enhanced keratinocyte cell–cell adhesion by intracellular O-glycosylation. J Biol Chem 281(18):12786–12791. doi:10.1074/jbc.M511702200 CrossRefPubMed

37.

Fukunaga Y, Liu H, Shimizu M, Komiya S, Kawasuji M, Nagafuchi A (2005) Defining the roles of beta-catenin and plakoglobin in cell–cell adhesion: isolation of beta-catenin/plakoglobin-deficient F9 cells. Cell Struct Funct 30(2):25–34CrossRefPubMed

38.

Lewalle JM, Bajou K, Desreux J, Mareel M, Dejana E, Noel A, Foidart JM (1997) Alteration of interendothelial adherens junctions following tumor cell–endothelial cell interaction in vitro. Exp Cell Res 237(2):347–356. doi:10.1006/excr.1997.3799 CrossRefPubMed

39.

Acehan D, Petzold C, Gumper I, Sabatini DD, Muller EJ, Cowin P, Stokes DL (2008) Plakoglobin is required for effective intermediate filament anchorage to desmosomes. J Invest Dermatol 128(11):2665–2675. doi:10.1038/jid.2008.141 CrossRefPubMed

40.

Palka HL, Green KJ (1997) Roles of plakoglobin end domains in desmosome assembly. J Cell Sci 110(Pt 19):2359–2371PubMed

41.

Ruiz P, Brinkmann V, Ledermann B, Behrend M, Grund C, Thalhammer C, Vogel F, Birchmeier C, Gunthert U, Franke WW, Birchmeier W (1996) Targeted mutation of plakoglobin in mice reveals essential functions of desmosomes in the embryonic heart. J Cell Biol 135(1):215–225CrossRefPubMed

42.

Kirchhof P, Fabritz L, Zwiener M, Witt H, Schafers M, Zellerhoff S, Paul M, Athai T, Hiller KH, Baba HA, Breithardt G, Ruiz P, Wichter T, Levkau B (2006) Age- and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation 114(17):1799–1806. doi:10.1161/CIRCULATIONAHA.106.624502 CrossRefPubMed

43.

Fabritz L, Hoogendijk MG, Scicluna BP, van Amersfoorth SC, Fortmueller L, Wolf S, Laakmann S, Kreienkamp N, Piccini I, Breithardt G, Noppinger PR, Witt H, Ebnet K, Wichter T, Levkau B, Franke WW, Pieperhoff S, de Bakker JM, Coronel R, Kirchhof P (2011) Load-reducing therapy prevents development of arrhythmogenic right ventricular cardiomyopathy in plakoglobin-deficient mice. J Am Coll Cardiol 57(6):740–750. doi:10.1016/j.jacc.2010.09.046 CrossRefPubMed

44.

Behrens J, Mareel MM, Van Roy FM, Birchmeier W (1989) Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell–cell adhesion. J Cell Biol 108(6):2435–2447CrossRefPubMed

45.

Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F (1991) Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66(1):107–119CrossRefPubMed

46.

Kundu ST, Gosavi P, Khapare N, Patel R, Hosing AS, Maru GB, Ingle A, Decaprio JA, Dalal SN (2008) Plakophilin3 downregulation leads to a decrease in cell adhesion and promotes metastasis. Int J Cancer 123(10):2303–2314. doi:10.1002/ijc.23797 CrossRefPubMed

47.

Gosavi P, Kundu ST, Khapare N, Sehgal L, Karkhanis MS, Dalal SN (2011) E-cadherin and plakoglobin recruit plakophilin3 to the cell border to initiate desmosome assembly. Cell Mol Life Sci 68(8):1439–1454. doi:10.1007/s00018-010-0531-3 CrossRefPubMed

48.

Parker HR, Li Z, Sheinin H, Lauzon G, Pasdar M (1998) Plakoglobin induces desmosome formation and epidermoid phenotype in N-cadherin-expressing squamous carcinoma cells deficient in plakoglobin and E-cadherin. Cell Motil Cytoskeleton 40(1):87–100. doi:10.1002/(SICI)1097-0169(1998)40:1<87:AID-CM8>3.0.CO;2-C CrossRefPubMed

49.

Li Z, Gallin WJ, Lauzon G, Pasdar M (1998) L-CAM expression induces fibroblast-epidermoid transition in squamous carcinoma cells and down-regulates the endogenous N-cadherin. J Cell Sci 111(Pt 7):1005–1019PubMed

50.

Franzen CA, Todorovic V, Desai BV, Mirzoeva S, Yang XJ, Green KJ, Pelling JC (2012) The desmosomal armadillo protein plakoglobin regulates prostate cancer cell adhesion and motility through vitronectin-dependent Src signaling. PLoS ONE 7(7):e42132. doi:10.1371/journal.pone.0042132 CrossRefPubMedCentralPubMed

51.

Tiwari I, Yoon MH, Park BJ, Jang KL (2015) Hepatitis C virus core induces epithelial–mesenchymal transition in human hepatocytes by upregulating E12/E47 levels. Cancer Lett. doi:10.1016/j.canlet.2015.03.032 PubMed

52.

Zhurinsky J, Shtutman M, Ben-Ze’ev A (2000) Plakoglobin and beta-catenin: protein interactions, regulation and biological roles. J Cell Sci 113(Pt 18):3127–3139PubMed

53.

Karnovsky A, Klymkowsky MW (1995) Anterior axis duplication in Xenopus induced by the over-expression of the cadherin-binding protein plakoglobin. Proc Natl Acad Sci USA 92(10):4522–4526CrossRefPubMedCentralPubMed

54.

Bradley RS, Cowin P, Brown AM (1993) Expression of Wnt-1 in PC12 cells results in modulation of plakoglobin and E-cadherin and increased cellular adhesion. J Cell Biol 123(6 Pt 2):1857–1865CrossRefPubMed

55.

Martin ED, Moriarty MA, Byrnes L, Grealy M (2009) Plakoglobin has both structural and signalling roles in zebrafish development. Dev Biol 327(1):83–96. doi:10.1016/j.ydbio.2008.11.036 CrossRefPubMed

56.

Spindler V, Dehner C, Hubner S, Waschke J (2014) Plakoglobin but not desmoplakin regulates keratinocyte cohesion via modulation of p38MAPK signaling. J Invest Dermatol 134(6):1655–1664. doi:10.1038/jid.2014.21 CrossRefPubMed

57.

Mao X, Li H, Sano Y, Gaestel M, Mo Park J, Payne AS (2014) MAPKAP kinase 2 (MK2)-dependent and -independent models of blister formation in pemphigus vulgaris. J Invest Dermatol 134(1):68–76. doi:10.1038/jid.2013.224 CrossRefPubMed

58.

Berkowitz P, Hu P, Liu Z, Diaz LA, Enghild JJ, Chua MP, Rubenstein DS (2005) Desmosome signaling. Inhibition of p38MAPK prevents pemphigus vulgaris IgG-induced cytoskeleton reorganization. J Biol Chem 280(25):23778–23784. doi:10.1074/jbc.M501365200 CrossRefPubMed

59.

Tokonzaba E, Chen J, Cheng X, Den Z, Ganeshan R, Muller EJ, Koch PJ (2013) Plakoglobin as a regulator of desmocollin gene expression. J Invest Dermatol 133(12):2732–2740. doi:10.1038/jid.2013.220 CrossRefPubMed

60.

Hoverter NP, Waterman ML (2008) A Wnt-fall for gene regulation: repression. Sci Signal 1(39):pe43. doi:10.1126/scisignal.139pe43 CrossRefPubMed

61.

Pan H, Gao F, Papageorgis P, Abdolmaleky HM, Faller DV, Thiagalingam S (2007) Aberrant activation of gamma-catenin promotes genomic instability and oncogenic effects during tumor progression. Cancer Biol Ther 6(10):1638–1643CrossRefPubMed

62.

Aktary Z, Pasdar M (2013) Plakoglobin represses SATB1 expression and decreases in vitro proliferation, migration and invasion. PLoS ONE 8(11):e78388. doi:10.1371/journal.pone.0078388 CrossRefPubMedCentralPubMed

63.

Cohen S, Lee D, Zhai B, Gygi SP, Goldberg AL (2014) Trim32 reduces PI3K-Akt-FoxO signaling in muscle atrophy by promoting plakoglobin-PI3K dissociation. J Cell Biol 204(5):747–758. doi:10.1083/jcb.201304167 CrossRefPubMedCentralPubMed

64.

Chen YJ, Lee LY, Chao YK, Chang JT, Lu YC, Li HF, Chiu CC, Li YC, Li YL, Chiou JF, Cheng AJ (2013) DSG3 facilitates cancer cell growth and invasion through the DSG3-plakoglobin-TCF/LEF-Myc/cyclin D1/MMP signaling pathway. PLoS ONE 8(5):e64088. doi:10.1371/journal.pone.0064088 CrossRefPubMedCentralPubMed

65.

Lai YH, Cheng J, Cheng D, Feasel ME, Beste KD, Peng J, Nusrat A, Moreno CS (2011) SOX4 interacts with plakoglobin in a Wnt3a-dependent manner in prostate cancer cells. BMC Cell Biol 12:50. doi:10.1186/1471-2121-12-50 CrossRefPubMedCentralPubMed

66.

Mathenge EG, Dean CA, Clements D, Vaghar-Kashani A, Photopoulos S, Coyle KM, Giacomantonio M, Malueth B, Nunokawa A, Jordan J, Lewis JD, Gujar SA, Marcato P, Lee PW, Giacomantonio CA (2014) Core needle biopsy of breast cancer tumors increases distant metastases in a mouse model. Neoplasia 16(11):950–960. doi:10.1016/j.neo.2014.09.004 CrossRefPubMedCentralPubMed

67.

Song GD, Sun Y, Shen H, Li W (2015) SOX4 overexpression is a novel biomarker of malignant status and poor prognosis in breast cancer patients. Tumour Biol. doi:10.1007/s13277-015-3051-9

68.

Aktary Z, Kulak S, Mackey J, Jahroudi N, Pasdar M (2013) Plakoglobin interacts with the transcription factor p53 and regulates the expression of 14-3-3sigma. J Cell Sci 126(Pt 14):3031–3042. doi:10.1242/jcs.120642 CrossRefPubMed

69.

Aberle H, Bierkamp C, Torchard D, Serova O, Wagner T, Natt E, Wirsching J, Heidkamper C, Montagna M, Lynch HT et al (1995) The human plakoglobin gene localizes on chromosome 17q21 and is subjected to loss of heterozygosity in breast and ovarian cancers. Proc Natl Acad Sci USA 92(14):6384–6388CrossRefPubMedCentralPubMed

70.

McPherson K, Steel CM, Dixon JM (2000) ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 321(7261):624–628CrossRefPubMedCentralPubMed

71.

Boersma BJ, Reimers M, Yi M, Ludwig JA, Luke BT, Stephens RM, Yfantis HG, Lee DH, Weinstein JN, Ambs S (2008) A stromal gene signature associated with inflammatory breast cancer. Int J Cancer 122(6):1324–1332. doi:10.1002/ijc.23237 CrossRefPubMed

72.

Korde LA, Lusa L, McShane L, Lebowitz PF, Lukes L, Camphausen K, Parker JS, Swain SM, Hunter K, Zujewski JA (2010) Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. Breast Cancer Res Treat 119(3):685–699. doi:10.1007/s10549-009-0651-3 CrossRefPubMed

73.

Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO (1994) Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 125(2):437–446CrossRefPubMed

74.

Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, Kieu C, Papior P, Baeuerle PA, Munz M, Gires O (2009) Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 11(2):162–171. doi:10.1038/ncb1824 CrossRefPubMed

75.

Galoian K, Qureshi A, Wideroff G, Temple HT (2015) Restoration of desmosomal junction protein expression and inhibition of H3K9-specific histone demethylase activity by cytostatic proline-rich polypeptide-1 leads to suppression of tumorigenic potential in human chondrosarcoma cells. Mol Clin Oncol 3(1):171–178. doi:10.3892/mco.2014.445 PubMedCentralPubMed

76.

Woelfle U, Cloos J, Sauter G, Riethdorf L, Janicke F, van Diest P, Brakenhoff R, Pantel K (2003) Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 63(18):5679–5684PubMed

77.

Bailey CK, Mittal MK, Misra S, Chaudhuri G (2012) High motility of triple-negative breast cancer cells is due to repression of plakoglobin gene by metastasis modulator protein SLUG. J Biol Chem 287(23):19472–19486. doi:10.1074/jbc.M112.345728 CrossRefPubMedCentralPubMed

78.

Shafiei F, Rahnama F, Pawella L, Mitchell MD, Gluckman PD, Lobie PE (2008) DNMT3A and DNMT3B mediate autocrine hGH repression of plakoglobin gene transcription and consequent phenotypic conversion of mammary carcinoma cells. Oncogene 27(18):2602–2612. doi:10.1038/sj.onc.1210917 CrossRefPubMed

79.

Stajduhar E, Sedic M, Lenicek T, Radulovic P, Kerenji A, Kruslin B, Pavelic K, Kraljevic Pavelic S (2014) Expression of growth hormone receptor, plakoglobin and NEDD9 protein in association with tumour progression and metastasis in human breast cancer. Tumour Biol 35(7):6425–6434. doi:10.1007/s13277-014-1827-y CrossRefPubMed

80.

Holen I, Whitworth J, Nutter F, Evans A, Brown HK, Lefley DV, Barbaric I, Jones M, Ottewell PD (2012) Loss of plakoglobin promotes decreased cell-cell contact, increased invasion, and breast cancer cell dissemination in vivo. Breast Cancer Res 14(3):R86. doi:10.1186/bcr3201 CrossRefPubMedCentralPubMed

81.

Storci G, Sansone P, Trere D, Tavolari S, Taffurelli M, Ceccarelli C, Guarnieri T, Paterini P, Pariali M, Montanaro L, Santini D, Chieco P, Bonafe M (2008) The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J Pathol 214(1):25–37. doi:10.1002/path.2254 CrossRefPubMed

82.

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750–2767. doi:10.1172/JCI45014 CrossRefPubMedCentralPubMed

83.

Alves CC, Carneiro F, Hoefler H, Becker KF (2009) Role of the epithelial–mesenchymal transition regulator Slug in primary human cancers. Front Biosci (Landmark Ed) 14:3035–3050CrossRef

84.

Shirley SH, Hudson LG, He J, Kusewitt DF (2010) The skinny on Slug. Mol Carcinog 49(10):851–861. doi:10.1002/mc.20674 CrossRefPubMedCentralPubMed

85.

Mittal MK, Myers JN, Misra S, Bailey CK, Chaudhuri G (2008) In vivo binding to and functional repression of the VDR gene promoter by SLUG in human breast cells. Biochem Biophys Res Commun 372(1):30–34. doi:10.1016/j.bbrc.2008.04.187 CrossRefPubMedCentralPubMed

86.

Mittal MK, Singh K, Misra S, Chaudhuri G (2011) SLUG-induced elevation of D1 cyclin in breast cancer cells through the inhibition of its ubiquitination. J Biol Chem 286(1):469–479. doi:10.1074/jbc.M110.164384 CrossRefPubMedCentralPubMed

87.

Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331(6024):1559–1564. doi:10.1126/science.1203543 CrossRefPubMed

88.

Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2(8):563–572. doi:10.1038/nrc865 CrossRefPubMed

89.

Plaks V, Koopman CD, Werb Z (2013) Cancer. Circulating tumor cells. Science 341(6151):1186–1188. doi:10.1126/science.1235226 CrossRefPubMed

90.

Labelle M, Begum S, Hynes RO (2014) Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci USA 111(30):E3053–E3061. doi:10.1073/pnas.1411082111 CrossRefPubMedCentralPubMed

91.

Ringner M, Fredlund E, Hakkinen J, Borg A, Staaf J (2011) GOBO: gene expression-based outcome for breast cancer online. PLoS ONE 6(3):e17911. doi:10.1371/journal.pone.0017911 CrossRefPubMedCentralPubMed

92.

Fredlund E, Staaf J, Rantala JK, Kallioniemi O, Borg A, Ringner M (2012) The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial–mesenchymal transition. Breast Cancer Res 14(4):R113. doi:10.1186/bcr3236 CrossRefPubMedCentralPubMed

Title: Circulating tumor cell clusters-associated gene plakoglobin and breast cancer survival
Authors: Lingeng Lu
Hongmei Zeng
Xinsheng Gu
Wenxue Ma
Publication date: 01-06-2015
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2015
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-015-3416-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells

Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis

TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li–Fraumeni family

Racial and ethnic differences in risk of second primary cancers among breast cancer survivors

Combined inhibition of glycolysis and AMPK induces synergistic breast cancer cell killing

Determining issues of importance for the evaluation of quality of life and patient-reported outcomes in breast cancer: results of a survey of 1072 patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer